AWP
PTCT icon

Abacus Wealth Partners’s PTC Therapeutics PTCT Stock Holding History

Abacus Wealth Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,340
Closed -$228K – 464
2026
Q1 		$228K Sell
3,340
-360
-10% -$25.5K 0.02% 438
2025
Q4 		$281K Buy
+3,700
New +$269K 0.03% 368

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Abacus Wealth Partners's PTCT Position: Q2 2026 in Review

Abacus Wealth Partners sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 3,340 shares — an estimated $228K sold.

Abacus Wealth Partners first reported a position in PTCT in Q4 2025 and held it in 2 quarters. The position peaked at $281K in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Abacus Wealth Partners reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Abacus Wealth Partners sold 3,340 PTC Therapeutics shares in Q2 2026, an estimated $228K.
  • Abacus Wealth Partners first reported a position in PTC Therapeutics in Q4 2025 and held it in 2 quarters.
  • Abacus Wealth Partners's PTC Therapeutics position peaked at $281K in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Abacus Wealth Partners's 13F filing for Q2 2026, filed 22 Jul 2026.